High-resolution HLA matching in hematopoietic stem cell transplantation: A retrospective collaborative analysis

Blood

Volumn 122, Issue 18, 2013, Pages 3220-3229

  Fürst, Daniel ^a,b   Müller, Carlheinz ^c,d   Vucinic, Vladan ^e   Bunjes, Donald ^b   Herr, Wolfgang ^f   Gramatzki, Martin ^g   Schwerdtfeger, Rainer ^h   Arnold, Renate ⁱ   Einsele, Hermann ^j   Wulf, Gerald ^k   Pfreundschuh, Michael ^l   Glass, Bertram ^m   Schrezenmeier, Hubert ^a,b   Schwarz, Klaus ^a,b   Mytilineos, Joannis ^a,b,d  

^a German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c ZKRD Zentrales Knochenmarkspender Register Deutschland   (Germany)

^d Deutsches Register für Stammzelltransplantationen DRST   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^k UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^l SAARLAND UNIVERSITY   (Germany)

^m DEPARTMENT OF CARDIOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; GROWTH FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD DONOR; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DONOR SELECTION; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HLA TYPING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

EID: 84888267552     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-482547     Document Type: Article

References (42)

1. Slavin S. Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients. Transplantation. 2004;78(7):964-965.
2. Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol. 2010;150(3):251-258.
3. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides 2011. Available at: http://www.cibmtr. org. Accessed May 19, 2013.
4. Gratwohl A, Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol. 2009;16(6):420-426.
5. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-819.
6. Fischer JC, Kobbe G, Enczmann J, Haas R, Uhrberg M. The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics. 2012;64(12):879-885.
7. Gratwohl A, Stern M, Brand R, et al; European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20):4715-4726.
8. European Group for Blood and Marrow Transplantation. MED-AB Forms Manual. A Guide to the completion of the EBMT HSCT Med-AB Forms. Appendix III. Available at: http://www.ebmt.org/Contents/Data-Management/Registrystructure/ MED-ABdatacollectionforms/Documents/MED-ABFormsManual.pdf. Accessed May 19, 2013.
9. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant. 2004;33(7):691-696.
10. National Marrow Donor Program. Policy for Confirmatory Typing Requirements. Available at: http://bioinformatics.nmdp.org/Policies/NMDP- Confirmatory-Typing-Requirements-(PDF).aspx. Accessed April 19, 2013.
11. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923-1930.
12. Lee SJ, Klein J, Haagenson M, et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583.
13. Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):885-892.
14. Hurley CK, Woolfrey A, Wang T, et al. The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. Blood. 2013;121(23):4800-4806.
15. Holdsworth R, Hurley CK, Marsh SG, et al. The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and-DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and-DQ antigens. Tissue Antigens. 2009;73(2):95-170.
16. Gourraud PA, Lamiraux P, El-Kadhi N, Raffoux C, Cambon-Thomsen A. Inferred HLA haplotype information for donors from hematopoietic stem cells donor registries. Hum Immunol. 2005;66(5):563-570.
17. Eberhard HP, Feldmann U, Bochtler W, Baier D, Rutt C, Schmidt AH, Müller CR. Estimating unbiased haplotype frequencies from stem cell donor samples typed at heterogeneous resolutions: a practical study based on over 1 million German donors. Tissue Antigens. 2010;76(5):352-361.
18. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. Berlin, Germany: Springer-Verlag; 2000:127-134.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA. 1999;94:496-509.
20. Iacobelli S; EBMT Statistical Committee. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48(Suppl 1):S1-S37.
21. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. Stat Med. 2004;23(3):369-388.
22. McNamee R. Regression modelling and other methods to control confounding. Occup Environ Med 2005;62(7):500-506.
23. Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens. 2007;69(6):545-556.
24. Spellman S, Klein J, Haagenson M, et al. Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(5):739-746.
25. Kawase T, Morishima Y, Matsuo K, et al; Japan Marrow Donor Program. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235-2241.
26. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012;367(9):805-816.
27. Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010;115(6):1166-1174.
28. Jöris MM, Lankester AC, Von Dem Borne PA, et al. The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT. Bone Marrow Transplant. 2013;48(4):483-490.
29. Petersdorf EW, Hansen JA. New advances in hematopoietic cell transplantation. Curr Opin Hematol. 2008;15(6):549-554.
30. Petersdorf EW, Malkki M, Gooley TA, Martin PJ, Guo Z. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med. 2007;4(1):e8.
31. Mullighan C, Heatley S, Doherty K, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stemcell transplantation. Transplantation. 2004;77(4):587-596.
32. Perreault C, Décary F, Brochu S, Gyger M, Bélanger R, Roy D. Minor histocompatibility antigens. Blood. 1990;76(7):1269-1280.
33. Fernández-Viña MA, Klein JP, Haagenson M, et al. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013;121(22):4603-4610.
34. Fleischhauer K, Shaw BE, Gooley T, et al; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13(4):366-374.
35. Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or-DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13(8):965-974.
36. Horan J, Wang T, Haagenson M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood. 2012;120(14):2918-2924.
37. Eapen M, Rocha V, Sanz G, et al; Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653-660.
38. Bray RA, Hurley CK, Kamani NR, et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant. 2008;14(9 Suppl):45-53.
39. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206.
40. Spellman SR, Eapen M, Logan BR, et al; National Marrow Donor Program; Center for International Blood and Marrow Transplant Research. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood. 2012;120(2):259-265.
41. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-3073.
42. Eapen M, Klein JP, Sanz GF, et al; Eurocord-European Group for Blood and Marrow Transplantation; Netcord; Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12(13):1214-1221.